Dabigatran, a specific, reversible direct thrombin inhibitor, is used to prevent ischaemic and
haemorrhagic strokes in patients with atrial fibrillation. As with every anticoagulant, there is a …

Objectives: To study dabigatran etexilate, a new oral anticoagulant that functions as a direct
thrombin inhibitor. Methods: This study evaluates four methods, one of which is performed in …

Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …

Background: Dabigatran etexilate (DE) is an orally absorbed prodrug of dabigatran, a
thrombin inhibitor that exerts potent anticoagulant and antithrombotic activity. Objectives: To …

Background Despite the well-studied safety profile of dabigatran, its interactions with genetic
polymorphism parameters are poorly understood, especially in patients with moderate …

Dabigatran, a direct thrombin inhibitor, is an oral anticoagulant indicated for the prevention
of stroke in patients with atrial fibrillation (AF) and for the treatment and prevention of deep …

Background—Renal impairment increases the risk of stroke and bleeding in patients with
atrial fibrillation. In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RELY) …

Essentials• Routine monitoring is unnecessary but measuring dabigatran levels is helpful in
certain situations.• We compared ecarin chromogenic assay (STA‐ECA‐II) and dilute …

Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent
thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is …

Dabigatran etexilate (DE) is the pro-drug of dabigatran (D), a synthetic low molecular weight
orally active reversible direct thrombin inhibitor. DE is approved for the prevention of stroke …